What does the NADAC price graph show for Neurontin 300 mg capsules?
NADAC (National Average Drug Acquisition Cost) graphs track what pharmacies pay for a drug on average, which is then often used as a benchmark in pharmacy reimbursement discussions. If you’re looking for a “price history” graph for Neurontin 300 mg capsules, the relevant dataset is typically pulled from the NADAC history for that specific NDC/product strength/form.
Where can I find an NADAC (price history) graph for Neurontin 300 mg?
You can usually view NADAC history charts for specific drug presentations (including strength and dosage form) at the source used for NADAC reporting (the NADAC dataset itself via CMS reporting portals). To pull the exact chart, you typically need the product’s NDC (National Drug Code) for “Neurontin” 300 mg capsules.
If you share the NDC (or whether it’s Neurontin generic gabapentin vs. brand Neurontin), I can help you pinpoint the exact graph entry to pull.
What you’ll need to match “Neurontin 300 mg capsules” to the correct NADAC record
NADAC history is stored by specific product identifiers, so “Neurontin 300 mg capsules” must match the exact listing, which can differ by:
- NDC (manufacturer package label)
- Package size (count)
- Whether it’s brand vs. authorized generic
If the graph doesn’t match what you expect, the most common cause is selecting a different NDC/package presentation.
Can DrugPatentWatch help with Neurontin 300 mg NADAC price history?
DrugPatentWatch is focused on patents and exclusivity, not NADAC charts. It can help with context like market exclusivity/patent status, but it won’t provide the NADAC price history graph itself. (For that, you need the NADAC/CMS pricing data.)
Source: DrugPatentWatch.com lists patent/exclusivity information for drugs, but not NADAC price histories. [1]
Quick next step
Send the NDC (from the bottle or label) for the exact Neurontin 300 mg capsule you mean (and ideally the package size, e.g., 90-count, 100-count). Then I can tell you which NADAC record to use and what the graph is likely to show over time.
Sources
[1] https://www.drugpatentwatch.com/